Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying
Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying
超级联赛企业和其他2只股票在$2以下，内部人士正在购买
The Dow Jones index closed lower by over 500 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道琼斯指数周三下跌超过500点。当内部人员购买或出售股票时，这表明他们对公司前景的信心或担忧。对于有兴趣投资或交易低价股票的投资者和交易者来说，可以考虑这一因素作为他们整体投资或交易决策的一个因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是几个近期关于低价股的值得关注的内部交易。了解更多，请查看Benzinga内幕交易平台。
Super League Enterprise
Super League Enterprise
- The Trade: Super League Enterprise, Inc. (NASDAQ:SLE) Director Jeff Patrick Gehl bought a total of 50,000 shares at an average price of $1.35. To acquire these shares, it cost around $67,548.
- What's Happening: On June 21, Super League issued a mid-year update from the Company's Chief Executive Office, Ann Hand.
- What Super League Enterprise Does: Super League Enterprise Inc is the rocket ship to the metaverse.
- 交易：Super League Enterprise，Inc.（NASDAQ：SLE）董事Jeff Patrick Gehl在平均价格为1.35美元的情况下购买了总共50,000股。要获得这些股份，花费大约67,548美元。
- 正在发生什么：6月21日，超级联赛（Super League）发布了公司首席执行官Ann Hand的半年度更新。
- 超级联赛企业是通往元宇宙的火箭船。
aTyr Pharma
atyr pharma
- The Trade: aTyr Pharma, Inc. (NASDAQ:ATYR) Director Paul Schimmel acquired a total of 100,000 shares at an average price of $1.85. To acquire these shares, it cost around $184,613.
- What's Happening: On July 22, HC Wainwright & Co. analyst Joseph Pantginis reiterated aTyr Pharma with a Buy rating and maintained a $35 price target.
- What aTyr Pharma Does: aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform.
- 交易：aTyr Pharma，Inc.（NASDAQ：ATYR）董事Paul Schimmel以平均价格1.85美元的价格购买了总共100,000股。购买这些股票的成本约为184,613美元。
- 动态：7月22日，HC Wainwright＆Co.分析师Joseph Pantginis重申对atyr pharma的买入评级，并维持35美元的目标价格。
- atyr pharma的业务是从其专有的tRNA合成酶平台发现和开发首创药物的生物治疗公司。
Retractable Technologies
Retractable Technologies
- The Trade: Retractable Technologies, Inc. (NYSE:RVP) President and CEO Thomas J Shaw acquired a total of 8,788 shares at an average price of $1.09. The insider spent around $9,579 to buy those shares.
- What's Happening: On May 15, Retractable Technologies posted a decline in quarterly sales results.
- What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.
- 交易：Retractable Technologies，Inc.（NYSE：RVP）总裁兼首席执行官Thomas J Shaw在平均价格为1.09美元的情况下购买了总共8,788股。内部人员花费了大约9,579美元购买这些股份。
- 正在发生什么事：5月15日，Retractable Technologies发布了季度销售结果下降的消息。
- Retractable Technologies Inc设计、开发、制造和销售安全注射器和其他医疗保健产品，为医疗保健行业提供安全解决方案。
- Nasdaq, S&P 500 Record Worst Session Since 2022 Amid Tesla, Alphabet Selloff: Investor Optimism Decreases Further
- 纳斯达克、标普500指数因特斯拉、Alphabet抛售而创下2022年以来最劣表现：投资者信心进一步降低。